Navigation Links
Orexigen® Therapeutics Reports First Quarter Ended March 31, 2011 Financial Results
Date:5/9/2011

SAN DIEGO, May 9, 2011 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the first quarter of 2011.  For the three months ended March 31, 2011, Orexigen reported a net loss of $11.6 million, or $0.24 per share, as compared to a net loss of $14.1 million, or $0.30 per share, for the first quarter of 2010.  As of March 31, 2011, Orexigen had $39.6 million in cash and cash equivalents and an additional $36.9 million in marketable securities, for a total of approximately $76.6 million.

"Over the last several months, together with our partner, Takeda, and our external advisors, we have been preparing for a meeting with FDA to discuss a viable path forward for Contrave®," said Michael Narachi, president and CEO of Orexigen. "We have submitted to the Agency a specific, innovative, and robust proposal to assess cardiovascular risk and have confirmed a meeting with the Agency later this quarter to discuss our proposal."

Total operating expenses for the first quarter of 2011 were $13.3 million compared to $14.0 million for the first quarter of 2010. This decrease in operating expenses primarily reflects a decrease in research and development expenses of $1.4 million principally related to the reduction in costs incurred in connection with the preparation for our NDA filing for Contrave in the first quarter of 2011 as compared to same period in 2010. This overall decrease was partially offset by an increase in general and administrative expenses principally related to one-time corporate realignment costs.

Conference Call Today at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time) The Orexigen management team will host a teleconference and webcast to discuss the first quarter 2011 financial results and recent business highlights. The l
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Orexigen® Therapeutics Reports Fourth Quarter and Year Ended December 31, 2010 Financial Results
2. Orexigen® Therapeutics Schedules March 10, 2011 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2010
3. Orexigen® Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer
4. Orexigen® Therapeutics Investigational Drug Contrave® Receives Positive Recommendation from FDA Advisory Committee for Treatment of Obesity
5. Orexigen® Therapeutics Reports Third Quarter 2010 Financial Results
6. Orexigen® Therapeutics to Speak at Fifth Annual JMP Securities Healthcare Conference
7. Orexigen® Therapeutics to Speak at Rodman & Renshaw Annual Global Investment Conference
8. Orexigen® Therapeutics and Takeda Enter Into Partnership to Commercialize Contrave® in North America
9. Orexigen® Therapeutics COR-BMOD Study Published in the Journal Obesity
10. Orexigen® Therapeutics Announces Publication of COR-I Phase 3 Study of Contrave in Lancet
11. Orexigen® Therapeutics Schedules August 5, 2010 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... et MADRID , June ... orale (extrait 10503) effectuée lors de la réunion ... PharmaMar communique que Janssen Research & ... de l,étude multicentrique de phase III SAR3007 qui ... progression (PFS) avec la trabectédine (YONDELIS ® ) ...
(Date:6/1/2015)... , June 2, 2015 Amgen ... with Roche on a Phase 1b study to ... Amgen,s investigational oncolytic immunotherapy, in combination with Roche,s ... in patients with triple-negative breast cancer and colorectal ... is an investigational oncolytic immunotherapy designed to selectively ...
(Date:6/1/2015)... June 1, 2015 Lee Tran ... the Snapchat and Yik Yak ... against one of the most promising biotechnology start-ups in ... Meyer and Jeffrey Sabados .  LTL represents ... a former colleague and fellow scientist at the Massachusetts ...
Breaking Medicine Technology:PharmaMar annonce que l'étude Janssen montre que la Trabectédine améliore la lutte contre la maladie chez les patients atteints du sarcome des tissus mous à un stade avancé 2PharmaMar annonce que l'étude Janssen montre que la Trabectédine améliore la lutte contre la maladie chez les patients atteints du sarcome des tissus mous à un stade avancé 3PharmaMar annonce que l'étude Janssen montre que la Trabectédine améliore la lutte contre la maladie chez les patients atteints du sarcome des tissus mous à un stade avancé 4PharmaMar annonce que l'étude Janssen montre que la Trabectédine améliore la lutte contre la maladie chez les patients atteints du sarcome des tissus mous à un stade avancé 5PharmaMar annonce que l'étude Janssen montre que la Trabectédine améliore la lutte contre la maladie chez les patients atteints du sarcome des tissus mous à un stade avancé 6Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 2Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 3Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 4Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 5Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 6Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 7Lee Tran & Liang LLP Files Co-Founder Lawsuit against Leading Biotech Start-up Resilience 2
... , ... ... ... ...
... ... ... ... , ...
Cached Medicine Technology:Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 2Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 3Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 4Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 5Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 6Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 7Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 8Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 9Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 10Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 11Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 12Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 13Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 14Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 15Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 16Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 17Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 18Poniard Pharmaceuticals Secures $20 Million Committed Equity Financing Facility 2Poniard Pharmaceuticals Secures $20 Million Committed Equity Financing Facility 3Poniard Pharmaceuticals Secures $20 Million Committed Equity Financing Facility 4Poniard Pharmaceuticals Secures $20 Million Committed Equity Financing Facility 5
(Date:6/1/2015)... 2015 On May 14, 2015, the ... hosted the Cherry Creek Chamber of Commerce for the ... care centers typically do not offer primary care services ... Cherry Creek Urgent Care staff to schedule family care ... 5:30 to 7:30 p.m. the center hosted presidents, CEOs, ...
(Date:6/1/2015)... EBSCO Health , a leading provider of ... , a cross-platform evidence-based clinical decision support tool for ... the ideal blend of evidence and expertise to help ... Plus is a significant enhancement over other tools currently ... evidence-based content. DynaMed Plus content is supplemented with full ...
(Date:6/1/2015)... (PRWEB) June 01, 2015 "This milestone ... who were not previously able to buy and sell ... on unsolicited orders and also make recommendations to clients ... investors an ability to trade shares of our Company,” ... compliance and information requirements of OTCQB provides our investors ...
(Date:6/1/2015)... Pittsburgh, PA (PRWEB) June 01, 2015 ... this new development in breast cancer prevention. , A ... Health suggests that postmenopausal women with ductal carcinoma in ... cancer treatment and prevention. , The study (NSABP B-35/NRG ... those who completed the standard five-year treatment with tamoxifen ...
(Date:6/1/2015)... (PRWEB) June 01, 2015 For years, ... requesting celebrity features. Much like one would request a ... noses, eyes, cheeks, chin and more to illustrate their ... apps like FaceTune are ushering in a new era ... facial plastic surgeon, Sam Rizk, MD, FACS notes that ...
Breaking Medicine News(10 mins):Health News:Grand Opening For AFC/Doctors Express Cherry Creek Primary Care Clinic 2Health News:EBSCO Health’s New DynaMed Plus™ Delivers Trusted, Evidence-Based Content to Physicians on Any Platform 2Health News:EBSCO Health’s New DynaMed Plus™ Delivers Trusted, Evidence-Based Content to Physicians on Any Platform 3Health News:EBSCO Health’s New DynaMed Plus™ Delivers Trusted, Evidence-Based Content to Physicians on Any Platform 4Health News:Content Checked Holdings Inc. Upgrades to the OTCQB Marketplace, now available for trading as CNCK 2Health News:Content Checked Holdings Inc. Upgrades to the OTCQB Marketplace, now available for trading as CNCK 3Health News:Content Checked Holdings Inc. Upgrades to the OTCQB Marketplace, now available for trading as CNCK 4Health News:Today at ASCO: Anastrazole Offers Higher Breast Cancer-Free Survival Rates than Tamoxifen Following DCIS, Phase III Study Shows 2Health News:Today at ASCO: Anastrazole Offers Higher Breast Cancer-Free Survival Rates than Tamoxifen Following DCIS, Phase III Study Shows 3Health News:Instagram Filters Launch New Facial Plastic Surgery Trend 2
... 27 MediSend International has joined The Clinton ... to Action , a unique feature of CGI ... measurable results. Through its Afghanistan Health and Human ... training, comprehensive repair and maintenance kits, technical support ...
... fibrillation, other arrhythmias , MONDAY, Oct. 26 (HealthDay ... hard evidence that the characteristic snorting and gasping ... abnormalities. , Previous studies have suggested an association ... had not established a cause-and-effect relationship, said study ...
... with pleasure that the Spain-United States Chamber of Commerce ... which is slated to increase attendance in 2009, will be held ... Nov. 6th. The gala recognizes Spain-native, U.S.-based companies and ... This year, The Chamber will honor IBT GROUP ...
... of severe physical, psychosocial suffering, researchers say , MONDAY, ... World War II, those who were potentially exposed to ... due to physical and mental stress, an Israeli study ... rates in more than 300,000 Israeli Jews who were ...
... that a sometimes deadly stomach bug, Clostridium difficile ... Clostridium difficile is a serious bacteria that ... of the colon. These findings were presented today at ... in San Diego. Clostridium difficile , often ...
... BOSTON, Oct. 26 Uno Chicago Grill®, America,s Healthiest Chain ... limited-time-only fall menu. , This exciting fall menu ... cranberries are a well-known and popular accent to many dishes, ... once the territory of a select few health food aficionados. ...
Cached Medicine News:Health News:MediSend International Joins the Clinton Global Initiative With the Afghanistan Health and Human Resource Initiative 2Health News:MediSend International Joins the Clinton Global Initiative With the Afghanistan Health and Human Resource Initiative 3Health News:Sleep Apnea Episodes May Trigger Irregular Heartbeat 2Health News:Spain-United States Chamber of Commerce Announces 30th Annual Gala Honoring IBT Group at The Biltmore Hotel - November 6 2Health News:Exposure to Holocaust May Have Raised Cancer Risks 2Health News:Deadly stomach infection rising in community settings, Mayo Clinic study finds 2Health News:Go, Go, Goji! UNO(R) Fall Menu Is 'Berry' Delicious 2Health News:Go, Go, Goji! UNO(R) Fall Menu Is 'Berry' Delicious 3
Refrigerator specially designed for the storage of blood in standard 500ml bags, complying with Australian Standard AS3864 1997....
TBR-120-1-GD is large capacity upright style refrigerator with an operating temperature of +4C. It is a specially designed refrigerator for the storage of blood in standard 500ml bags, complying with...
TBR-720-2-GD is large capacity upright style operating temperature +4C. It is specially designed refrigerators for the storage of blood in standard 500ml bags, complying with Australian Standard AS38...
... is a direct competitive EIA for ... human serum or plasma. A specific ... making it available for antibody binding. ... antibody linked to fluorescein isothiocyanate (FITC) ...
Medicine Products: